Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Achiron, Anat ^a   Feldman, Anna ^a   Magalashvili, David ^a   Dolev, Mark ^a   Gurevich, Michael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; DNA DIRECTED RNA POLYMERASE; IMMUNOMODULATING AGENT;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PROTEIN MOTIF; RELAPSE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADULT; APOPTOSIS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POL1 TRANSCRIPTION INITIATION COMPLEX PROTEINS; RNA POLYMERASE I; SIGNAL TRANSDUCTION;

EID: 84867422424     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046871     Document Type: Article

References (27)

1. Confavreux C, Vukusic S, (2008) The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am 18: 589-622, ix-x.
2. Glad SB, Nyland HI, Aarseth JH, Riise T, Myhr KM, (2009) Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Mult Scler pp. 942-950.
3. Ramsaransing GS, De Keyser J, (2007) Predictive value of clinical characteristics for 'benign' multiple sclerosis. Eur J Neurol 14: 885-889.
4. Hawkins SA, McDonnell GV, (1999) Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67: 148-152.
5. Poser S, Wikström J, Bauer HJ, (1979) Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 40: 159-168.
6. Hutchinson M, (1986) Disability due to multiple sclerosis: a community-based study of an Irish county. Ir Med J 79: 48-50.
7. Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, et al. (2008) Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 205: 113-125.
8. Brynedal B, Khademi M, Wallström E, Hillert J, Olsson T, et al. (2010) Gene expression profiling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis 37: 613-621.
9. Satoh J, Illes Z, Peterfalvi A, Tabunoki H, Rozsa C, et al. (2007) Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neurosci Lett 422: 30-33.
10. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M, (2004) Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 55: 410-417.
11. Lublin F, Reingold S, (1996) The national multiple sclerosis society USA advisory committee on clinical trails of new agents in multiple sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46: 907-911.
12. Kalita K, Makonchuk D, Gomes C, Zheng JJ, Hetman M, (2008) Inhibition of nucleolar transcription as a trigger for neuronal apoptosis. J Neurochem 105: 2286-2299.
13. Yuan X, Zhou Y, Casanova E, Chai M, Kiss E, et al. (2005) Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol Cell 19: 77-87.
14. Rao A, Luo C, Hogan PC, (1997) Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15: 707-747.
15. Rincon M, Flavell RA, (1997) Transcription mediated by NFAT is highly inducible in effector CD4+ T helper 2 (Th2) cells but not in Th1 cells. Mol Cell Biol 17: 1522-1534.
16. Shinmen N, Koshida T, Kumazawa T, Sato K, Shimada H, et al. (2009) Activation of NFAT signal by p53-K120R mutant. FEBS Lett 583: 1916-1922.
17. Hirschler-Laszkiewicz I, Cavanaugh AH, Mirza A, Lun M, Hu Q, et al. (2003) Rrn3 becomes inactivated in the process of ribosomal DNA transcription. J Biol Chem 278: 18953-18959.
18. Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, et al. (2003) Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA 100: 605-610.
19. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, et al. (2004) A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004 6: 97-105.
20. Achiron A, Gurevich M, Snir Y, Segal E, Mandel M, (2007) Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis. Clin Exp Immunol 149: 235-242.
21. Wang Y, Mei Y, Feng D, Xu L, (2008) Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurosci Res 86: 2441-2449.
22. Weichhart T, (2012) Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods Mol Biol 821: 1-14.
23. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, et al. (2010) Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 28: 835-840.
24. Esposito M, Ruffini F, Bellone M, Gagliani N, Battaglia M, et al. (2010) Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol 220: 52-63.
25. Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, et al. (2012) Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis. J Neuroimmunol 243: 43-51.
26. Tsang CK, Liu H, Zheng XF, (2010) mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes. Cell Cycle 9: 953-957.
27. Philippi A, Steinbauer R, Reiter A, Fath S, Leger-Silvestre I, et al. (2010) TOR-dependent reduction in the expression level of Rrn3p lowers the activity of the yeast RNA Pol I machinery, but does not account for the strong inhibition of rRNA production. Nucleic Acids Res 38: 5315-5326.